NEW YORK (GenomeWeb) – Having earlier this month unveiled its plan to merge with hepatitis B therapeutics firm OnCore Biopharma, Tekmira Pharmaceuticals has provided a few details about its drug-development plans going forward in a recent filing with the US Securities and Exchange Commission.

Going forward, Tekmira aims to make its siRNA-based HBV therapy TKM-HBV the foundation of a treatment regimen that will also include one or two other drugs from OnCore's pipeline of preclinical candidates, it said in the SEC filing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.